You are here
Synergen Inc
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
ANTIPLAQUE PROTEINS VIA GENETIC ENGINEERING
Amount: $440,212.00SYNERGEN, INC.'S PROPOSED RESEARCH WILL DEVELOP, THROUGH RECOMBINANT DNA METHODS, NEW AGENTS TO CONTROL DENTAL PLAQUETHESE WILL CONSIST OF AN ENZYMATIC MOIETY OF THERAPEUTIC VALUE FUSED WIH AN ADHESIV ...
SBIRPhase II1989Department of Health and Human Services -
KALLIKREIN INHIBITORS BY GENETIC ENGINEERING
Amount: $50,000.00THE AIM OF THIS RESEARCH IS TO PRODUCE INHIBITORS OF HUMAN KALLIKREINS THAT BLOCK KALLIKREIN-MEDIATED CONVERSION OF KININOGENS INTO KININS. KININS ARE IMPLICATED IN THE SYMPTOMS OF ALLERGIC RHINITIS, ...
SBIRPhase I1989Department of Health and Human Services -
NEW DRUG FOR PREVENTING POST-ISCHEMIC TISSUE INJURY
Amount: $50,000.00NEUTROPHILS ARE A MAJOR CONTRIBUTOR TO THE CELLULAR DAMAGE THAT ACCOMPANIES REPERFUSION OF ISCHEMIC TISSUES. IT IS PLANNED TO CLONE AND PRODUCE THROUGH RECOMBINANT DNA METHODS A HUMAN PROTEIN THAT BLO ...
SBIRPhase I1989Department of Health and Human Services -
VACCINE AGAINST HAEMOPHILUS INFLUENZAE TYPE B
Amount: $49,766.00THIS RESEARCH WILL LEAD TO THE DEVELOPMENT OF A VACCINE THAT CAN BE USED TO PROTECT YOUNG CHILDREN AGAINST INFECTIONS CAUSED BY HAEMOPHILUS INFLUENZAE TYPE B (HIB). THE VACCINE WILL BE BASED ON THE PI ...
SBIRPhase I1989Department of Health and Human Services -
DEVELOPMENT OF AMIDASES FOR USE IN BETA-LACTAM MODIFICATION
Amount: $50,000.00SEVERAL CLINICALLY IMPORTANT BETA-LACTAM ANTIBIOTICS ARE PRODUCED THROUGH CONDENSATION OF D-(-)-ALPHA-AMINOPHENYLACETIC ACID WITH PENAM AND CEPHEM NUCLEI IN MULTI-STEP CHEMICAL PROCESSES. AN EFFICIENT ...
SBIRPhase I1988Department of Health and Human Services -
THERAPEUTIC CLEARANCE OF COMPLEMENT FRAGMENT C5A
Amount: $50,000.00THE OVERALL GOAL OF THE PROPOSED RESEARCH IS TO PROVIDE A SPECIFIC, PRACTICAL MEANS FOR INACTIVATING C5A IN PATIENTS AT RISK OF ADULT RESPIRATORY DISTRESS SYNDROME (ARDS). C5A IS A KEY CONTRIBUTORY, P ...
SBIRPhase I1988Department of Health and Human Services -
A HUMAN IL-1 INHIBITOR FOR THE TREATMENT OF SEPTIC SHOCK
Amount: $49,326.00WE PROPOSE TO PURIFY AN IL-1 INHIBITOR FROM THE SUPERNATANT OF MONOCYTES CULTURED ON PLATES COATED WITH IGG. THIS INHIBITORY ACTIVITY HAS BEEN SHOWN TO BE ABOUT 22 KILODALTONS IN MOLECULAR WEIGHT AND ...
SBIRPhase I1988Department of Defense Navy -
ANTIPLAQUE PROTEINS VIA GENETIC ENGINEERING
Amount: $50,000.00N/A
SBIRPhase I1987Department of Health and Human Services